




   




   
 
    
   
  








   
    
  
  
   




   
 
Common Elements in Guidelines for Prescribing Opioids for Chronic Pain 

The use of opioids for treating chronic pain has been increasing.1 In 2010, an estimated 20% of patients presenting to physician offices in the United States with pain symptoms or diagnoses were prescribed opioids.2 Improving the 
way opioids are prescribed through clinical practice guidelines can ensure patients have access to safe, effective treatment while reducing the number of people who misuse, abuse or overdose from these powerful drugs.
The Centers for Disease Control and Prevention’s (CDC) National Center for Injury Prevention and Control, along with the National Institute on Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration
(SAMHSA), and the Office of the National Coordinator for Health Information Technology (ONC), reviewed eight guidelines to identify common recommendations (see accompanying Table).  Guidelines on chronic pain that had been
issued on or before January 2013 and developed by professional societies, states, or Federal agencies for general practitioners were considered. Guidelines for specific conditions or subpopulations were excluded, as were those 
specific to pain specialists.
Guidelines varied by development methodology (systematic review, expert opinion) and conflict of interest management (disclosure, voting recusal) (see Table). According to the Institute of Medicine, trustworthy clinical practice 
guidelines appropriately manage conflict of interest, use systematic reviews of the evidence to inform recommendations, and rate the strength of the evidence and recommendations.3 
The following guidelines were reviewed:   
 American Pain Society/American Academy of Pain Medicine Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain (2009)4 
 Utah State Clinical Guidelines on Prescribing Opioids for Treatment of Pain (2009)5 
 Veterans Affairs/Department of Defense Management of Opioid Therapy for Chronic Pain (2010)6 
 Washington State Agency Medical Directors Group Interagency Guideline on Opioid Dosing for Chronic Noncancer Pain (2010)7 
 Canadian Guideline for Safe and Effective Use of Opioids for Chronic Noncancer Pain (2011)8 
 American College of Occupational and Environmental Medicine Guidelines for the Chronic Use of Opioids (2011)9 
 New York City Department of Health and Mental Hygiene Opioid Prescribing Guidelines (2011)10 
 American Society of Interventional Pain Physicians Guidelines for Responsible Opioid Prescribing in Chronic Noncancer Pain (2012)11 
Recommendations from each of these guidelines were reviewed, extracted, and coded into categories of provider actions associated with pre-treatment, initial opioid treatment, follow-up, and discontinuation phases. This process 
resulted in a common set of provider actions and associated recommendations that can be seen in the table. 
Common recommendation elements found in all the guidelines include: 
 Conducting a physical exam, pain history, past medical history, and family/social history 
 Conducting urine drug testing, when appropriate
 Considering all treatment options, weighing benefits and risks of opioid therapy, and using opioids when alternative treatments are ineffective
 Starting patients on the lowest effective dose
 Implementing pain treatment agreements
 Monitoring pain and treatment progress with documentation; using greater vigilance at high doses
 Using safe and effective methods for discontinuing opioids (e.g., tapering, making appropriate referrals to medication-assisted treatment, substance use specialists, or other services)  
An additional recommendation element appearing in several guidelines that will become more feasible as states enhance their data systems includes:
 Using data from Prescription Drug Monitoring Programs (PDMPs) to identify past and present opioid prescriptions at initial assessment and during the monitoring phase 
It is useful to identify common recommendation elements across guidelines to help inform others who may be considering developing their own guidelines.  
In addition, rigorous, evidence-based recommendations can be incorporated into clinical decision support, such as within the electronic health record, to make it easier for health providers to
follow guidelines. 
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Provider Action 
Guideline Recommendations
APS/AAPM Utah VA/DoD WA State Canadian ACOEM NYC ASIPP 
PRE-TREATMENT 
Pain history Conduct history; diagnostic tests 
to evaluate pain condition
Assess prior treatment of 
pain 












Conduct detailed pain 
history 
Conduct detailed history
that includes medications, 
onset, location, quality, 





pain intensity and 
functional
impairment 
Past medical history Conduct history; substance 
abuse/misuse/addiction testing 
Assess medical and 
mental health
conditions, medications, 
substance addiction or 
dependence



























assessment and family history 
Assess social history Concurrent 














Pregnancy Counsel women of childbearing 
potential; Minimal/no use 
during pregnancy; Anticipate 
and manage risks during 
pregnancy 
Not addressed Estimate risk of
opioid therapy in 
pregnancy 




Not addressed Not addressed Not addressed
Prescription Drug 
Monitoring Program 
- Initial assessment 
of past use 
Not addressed Check PDMP Not addressed Not addressed Check PDMP Not addressed Check PDMP Check PDMP
Physical Exam Conduct physical exam Assess pain severity, 


























































APS/AAPM Utah VA/DoD WA State Canadian ACOEM NYC ASIPP 
Laboratory - Urine Not addressed Perform before initiating Obtain in all Conduct baseline Conduct Conduct at baseline Consider for all patients Must be used to
Drug Screening long term opioids patients prior to on all current baseline establish a baseline 
initial assessment initiation of opioids. prescription 





measure of risk measure of risk
Opioid Indication Consider alternatives to opioids 
and trial when benefits are likely 
to outweigh risks and no 
alternative therapy likely to pose 
favorable benefit/harm balance 




considered only when 




drug or non-opioid 
modalities, or when 
benefits outweigh 









to use (e.g., 
substance abuse) 










benefits are likely to
outweigh potential harm; 
when other approaches to 
analgesia are ineffective
Establish medical 











INITIAL OPIOID TREATMENT 
Drug choice Initial therapeutic trial (weeks to 
months); Selection, dosing, 
titration individualized based on 
health status, opioid exposure, 
goals, and harms 
Short term trial; start 
with short acting opioids






selecting a specific 
opioid 
Trial of short 
acting opioids 
before long acting 
Select opioid
















Short acting opioids for 
acute pain; avoid long
acting opioids; do not 
consider opioids first line 
for chronic non-cancer pain
Start with short 
acting opioids; 




Methadone Initiate and titrate cautiously by 
clinicians familiar with use/risks 
Prescribed by clinicians 














Not addressed Additional caution needed Use after failure of
other opioids; use 
by clinicians with 
specific training in
















        






































APS/AAPM Utah VA/DoD WA State Canadian ACOEM NYC ASIPP 
Starting dosage Start at low dose and titrate 
slowly
Start at low dose and
titrate slowly
Start at low dose Use lowest
effective dose 
Start at low 
dosage, increase 
gradually
Start with low dose Start with the lowest
possible effective dose
Start at low dosage, 
increase 
gradually
Duration of initial 
treatment
Several weeks to months Short term trial Not addressed Not addressed Not addressed Not to exceed 4 weeks; in
rare situations may 
extend by 2 weeks 
Not addressed 8 to 12 weeks
Co-prescribing Not addressed Close attention to 
benzodiazepines/other 
sedatives 











Evaluate based on 
individual patient needs 
Avoid benzodiazepines or 
other depressants 






Documentation Informed consent; Written 
management plan 
Written treatment plan; 
Informed consent; 
written education 





























Treatment progress Monitor pain intensity, level of 
functioning, progress toward 
goals, adverse events, 
adherence; assess aberrant
drug-related behaviors, 
substance use, psychological 
issues 
Regular visits with 
evaluation of progress; 















abuse at each visit 
Assess pain 
intensity and










Regular follow-up visits; 










High-dose opioids >200mg/day; more frequent 




Refer or consult if












>100 MME/day, reassess 









    








































APS/AAPM Utah VA/DoD WA State Canadian ACOEM NYC ASIPP 












in patients taking 
tricyclic, SSRI, or SNRI 
anti-depressants 
Avoid prescribing opioids
with benzodiazepines or 
other depressants 









Routine behavior assessment; 
Check PDMP 
Check PDMP regularly Not addressed Not addressed Check PDMP Not addressed Routine behavior 
assessment; Check PDMP 
Continued PDMP 
checks 
Laboratory - Urine 
Drug Screening 
Monitoring
If high risk, periodic urine drug 
screens; if not high risk, consider 
periodic screens 
Randomly selected visits 
and when aberrant 
behavior is suspected 
Conduct randomly 
at follow-up visits, 
increase frequency 
based on risk level 
Random testing 
based on risk 
category










least once and up to 4
times a year and at
termination
Repeat randomly, based on 
risk level (yearly for low









in repeated aberrant drug-
related behaviors or 
abuse/diversion; no progress; 
intolerable adverse effects
Document 
nonadherence to the 
treatment plan;
discontinue if goals are
not met, if adverse 
effects outweigh
benefits or if dangerous 
or illegal behaviors are 
demonstrated
Document any 
evidence of misuse, 






aspects of opioid 
trial; discontinue 
if pain remains 
unresponsive 
Failure to improve; 
aberrant behaviors
Document all aspects of 
opioid trial; discontinue if
signs of opioid misuse 
Document all 
aspects of opioid 
trial; consider taper 
or discontinue if no 
improvement, 
adverse effects or 
aberrant behavior 
Tapering plan Slow 10% reduction/week to 
rapid 25%-50% reduction/few 
days
10% reduction/week
over 6 to 8 weeks 
Taper by 20%-50% 
per week; faster or 
slower tapering
may be warranted 
10% 
reduction/week 
over 6 to 8 weeks 
Variable; 10% of
the total daily 
dose every day, 
or 10% of the 
total daily dose
every 1–2 weeks 
Not addressed Reduction of 10% each day,
20% every 3 to 5 days, or 
25% each week
Decrease by 10% of






























     
 
         
            
          
                 
           
          
                  
         





APS/AAPM Utah VA/DoD WA State Canadian ACOEM NYC ASIPP 
Referral for Make treatment available and Consider consultation Refer to SUD If signs of alcohol When needed, Referral for mental Explain the option of Assess for 
Medication Assisted arrange continued follow-up for complex cases or specialty when or substance consult pain health, substance use buprenorphine and refer to abuse/addiction 
Treatment or other referral to a pain behavior suggests abuse refer to an management or specialist, pain an addiction specialist, and refer for
substance abuse management, mental addiction; refer to addiction addiction management specialist buprenorphine provider, or addiction
treatment services health or substance use behavioral health specialist specialists; methadone maintenance treatment and pain 




treatment program management as 
appropriate 
problems intervention
GUIDELINE DEVELOPMENT METHODS 

















grading approval; Preventive Services 





Conflicts of Interest Disclosed; recused from voting Disclosed Not addressed Not addressed Disclosed Not addressed Not addressed Disclosed 
Guidelines  
APS/AAPM = American Pain Society/American Academy of Pain Medicine Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer  Pain  
Utah = Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain  
VA/Dod = Veteran's Administration/Department of Defense Management  of  Opioid Therapy  for  Chronic  Pain  
WA State = Washington State Agency Medical Directors Group Interagency Guideline on Opioid Dosing for Chronic Noncancer Pain
Canadian = Canadian Guideline for Safe and Effective Use of Opioids for Chronic Noncancer Pain
ACOEM = American College of Occupational and Environmental Medicine  Guidelines  for  the  Chronic  Use  of  Opioids  
NYC = New York City Department of Health and Mental Hygiene Opioid Prescribing Guidelines 
ASIPP = American Society of Interventional Pain Physicians Guidelines for Responsible Opioid Prescribing in Chronic Noncancer Pain  
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